Azienda Ospedaliera `San Giovanni di Dio e Ruggi D'Aragona` Struttura Complessa di Oncologia
Welcome,         Profile    Billing    Logout  
 3 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAVASTANO, CLEMENTINA
OINC, NCT04480268: PAXG Out in the Country

Recruiting
4
175
Europe
PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
IRCCS San Raffaele
Pancreatic Ductal Adenocarcinoma
01/22
01/26
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAVASTANO, CLEMENTINA
OINC, NCT04480268: PAXG Out in the Country

Recruiting
4
175
Europe
PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
IRCCS San Raffaele
Pancreatic Ductal Adenocarcinoma
01/22
01/26
HERMIONE-7, NCT04227327: Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients

Active, not recruiting
2
31
Europe
Abemaciclib, Aromatase Inhibitors
University of Milano Bicocca
Advanced Breast Cancer
12/23
12/23
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25

Download Options